Our Firm is representing numerous men and young boys whose Risperdal lawsuits allege symptoms associated with gynecomastia following use of the medication.
New York, NY (PRWEB) December 03, 2014
A meeting to discuss Risperdal lawsuits (http://www.risperdallawsuit2014.com/) took place this week in the Philadelphia Court of Common Pleas, where a consolidated litigation is currently underway, Bernstein Liebhard LLP reports.
According to a Calendar posted on the Pennsylvania court’s website, parties involved in the proceeding met on Tuesday, December 2nd to discuss state-filed lawsuits over the antipsychotic medication. Among the items listed on the Court’s agenda were likely matters related to claims alleging Risperdal gynecomastia, a condition referring to male breast development, and other complications. (In Re: Risperdal Litigation, Case Number 100300296).
“Our Firm is representing numerous men and young boys whose Risperdal lawsuits allege symptoms associated with gynecomastia following use of the medication. These lawsuits further allege that it was often prescribed off-label, especially in the treatment of children,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case evaluations to men and boys who claim to have developed male breasts, or gynecomastia, after taking Risperdal.
Risperdal Litigation
According to court records updated recently, more than 1,100 Risperdal lawsuits are now pending in the Philadelphia Court of Common Pleas, where Bernstein Liebhard LLP is actively filing claims. All lawsuits filed by the Firm allege side effects associated with gynecomastia, which may include swollen or painful breasts, lactation, diagnosis of gynecomastia and/or surgical treatment of the condition. Plaintiffs in Risperdal lawsuits accuse Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, of failing to warn patients and doctors about the medication’s potential to cause the body to produce excess amounts of prolactin, a hormone typically associated with female breast growth and lactation. The companies also engaged in improper marketing practices involving Risperdal for off-label pediatric uses, plaintiffs allege.
Similar claims against Johnson & Johnson and Janssen have also been made by the U.S. Department of Justice, which they agreed to settle in November 2013 for more than $2.2 billion. Among other things, the companies were charged with misbranding Risperdal as a treatment for elderly patients with dementia, and to children, which they pled guilty to. According to the federal government, the agreement was among the largest healthcare fraud settlements in U.S. history. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Risperdal is an atypical antipsychotic medication approved by the U.S. Food and Drug Administration (FDA) to treat schizophrenia and bipolar disorder in adults and adolescents ages 10-to-17, and for symptoms of irritability in children between the ages of 5-and-16 with autistic disorder. Recent research suggests that Risperdal has been frequently prescribed for ADHD, despite its lack of approval for this use by regulators.*
Men and young boys who allegedly developed gynecomastia due to their use of Risperdal may be eligible to receive compensation for medical bills, lost wages, pain and suffering and other injury-related damages. Learn more about filing a Risperdal lawsuit by visiting Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.
*health.usnews.com/health-news/news/articles/2012/08/07/more-kids-taking-antipsychotics-for-adhd-study, U.S. News & World Report, August 7, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuit2014.com/
https://plus.google.com/115936073311125306742?rel=author